Items Tagged ‘Precision Medicine PD-1’

April 13th, 2017

Opdivo Appears to Significantly Improve Five-Year Survival Rates in Advanced Lung Cancer


Treatment with the immune checkpoint inhibitor Opdivo (nivolumab) yielded durable responses in some patients with advanced non-small cell lung cancer (NSCLC), with a five-year survival rate of 16 percent, according to data presented here at the AACR Annual Meeting in Washington DC this week. Lung cancer remains the leading cause of cancer-related deaths in the […]

View full entry

Tags: Lung Cancer, Lung Cancer - Non-Small Cell, News, nsclc, opdivo, Precision Medicine PD-1